In recent trading session, Novo Nordisk ADR (NYSE:NVO) saw 2.32 million shares changing hands at last check today with its beta currently measuring 0.67. Company’s recent per share price level of $61.40 trading at -$1.23 or -1.97% at last check today assigns it a market valuation of $206.54B. That most recent trading price of NVO’s stock is at a discount of -141.29% from its 52-week high price of $148.15 and is indicating a premium of 7.17% from its 52-week low price of $57.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 11.6 million shares which gives us an average trading volume of 8.73 million if we extend that period to 3-months.
For Novo Nordisk ADR (NVO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.03. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 6.07 in the current quarter.
Novo Nordisk ADR (NYSE:NVO) trade information
Upright in the red during last session for losing -1.97%, in the last five days NVO remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $61.40 price level, adding 2.14% to its value on the day. Novo Nordisk ADR’s shares saw a change of -28.63% in year-to-date performance and have moved 5.71% in past 5-day. Novo Nordisk ADR (NYSE:NVO) showed a performance of -14.41% in past 30-days. Number of shares sold short was 14.66 million shares which calculate 2.08 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 158 to the stock, which implies a rise of 61.14% to its recent value today. Analysts have been projecting 156 as a low price target for the stock while placing it at a high target of 160. It follows that stock’s current price would drop -154.07% in reaching the projected high whereas dropping to the targeted low would mean a loss of -154.07% for stock’s current value.
Novo Nordisk ADR (NVO) estimates and forecasts
This year revenue growth is estimated to rise 19.27% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 77.81B for the same. And 7 analysts are in estimates of company making revenue of 79.86B in the next quarter. Company posted 65.35B and 68.06B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 24.90% while estimates for its earnings growth in next 5 years are of 19.67%.
NVO Dividends
Novo Nordisk ADR is more likely to be releasing its next quarterly report on 2025-Feb-04 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 2.70%, the share has a forward dividend of 1.66 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 1.44%.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
Insiders are in possession of 0.00% of company’s total shares while institution are holding 10.28 percent of that, with stock having share float percentage of 10.28%. Investors also watch the number of corporate investors in a company very closely, which is 10.28% institutions for Novo Nordisk ADR that are currently holding shares of the company. JENNISON ASSOCIATES LLC is the top institutional holder at NVO for having 21.22 million shares of worth $3.03 billion. And as of 2024-06-30, it was holding 0.476 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 19.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 0.4373 of outstanding shares, having a total worth of $2.78 billion.
On the other hand, Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd. and HARBOR FUNDS-Harbor Capital Appreciation Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 4.82 shares of worth $296.66 million or 0.14% of the total outstanding shares. The later fund manager was in possession of 4.22 shares on Jan 31, 2025 , making its stake of worth around $259.61 million in the company or a holder of 0.12% of company’s stock.
